Xenetic Biosciences, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.xeneticbio.com

Moat Score

Market Cap $4.45M
PE -1
Debt -
Cash $5.16M
EV -
FCF -

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$3.67M
EBIT	-$3.88M
ROE	-72%
ROA	-67%
Equity	$5.12M
Growth Stability	1
PE	-1.21
PB	0.87
P/S	1.72
Price/Cash	1.16
Net Margins	-152%
Op. Margins	-150%
Sales Growth YoY	16%
Sales Growth QoQ	-9%
Sales CAGR	2%
Equity CAGR	2%
Earnings Growth YoY	-24%
Earnings Growth QoQ	-14%

Sales CAGR 5Y	62%
Equity CAGR 5Y	-15%
Earnings CAGR 3Y	23%
Sales CAGR 3Y	23%
Equity CAGR 3Y	-33%
Market Cap	$4.45M
Revenue	$2.58M
Assets	$5.79M
Cash	$5.16M
Shares Outstanding	1.54M
Moat Score	1%
Working Capital	4.81M
Current Ratio	8.2
Shares Growth 3y	4%
Equity Growth QoQ	-15%
Equity Growth YoY	-41%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Xenetic Biosciences Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The company is initially advancing cell-based therapeutics targeting B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a pipeline of therapeutic assets targeting oncology indications. It also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin resistant endometrial cancer.

SEC Filings

Direct access to Xenetic Biosciences, Inc. (XBIO) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2025
- 10-Q Mar 31
2024
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Xenetic Biosciences, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Xenetic Biosciences, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Xenetic Biosciences, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Xenetic Biosciences, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Net Margins	-	-2K%	-47%	-	-106K%	-3K%	-486%	-384%	-163%	-158%	-152%
ROA	-	-226%	-19%	-50%	-60%	-106%	-29%	-46%	-43%	-61%	-67%
ROE	-	-360%	-25%	-74%	-105%	-113%	-31%	-48%	-42%	-66%	-72%

Bad Net Margins (-152.23%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	TTM
Debt over FCF	-	-	-	-	-	-	-	-	-	-	-
Debt over Equity	-	-	-	-	-	-	-	-	-	-	-
Growth Stability	-	-	-	-	-	-	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Neutral Debt/Equity ratio (-)

The company has a balance between equity and debt that is not too good nor too bad.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2015	12/2016	12/2017	12/2018	12/2019	12/2020	12/2021	12/2022	12/2023	12/2024	CAGR 5Y
Revenue YoY growth	-	-	153%	-100%	-	2K%	166%	47%	49%	-2%	62%
Earnings YoY growth	-	366%	-94%	103%	147%	-24%	-59%	16%	-37%	-4%	-
Equity YoY growth	-	145%	-12%	-31%	74%	-29%	51%	-26%	-28%	-39%	-15%
FCF YoY growth	-	66%	-117%	-535%	-	-	-	-	-	-	-